Medical Xpress reports that Argyrin B largely spared beneficial gut bacteria, but its optimal dose remains unresolved.
Medical Xpress reports that Argyrin B suppressed C. difficile in laboratory tests and infected mice while largely sparing beneficial gut bacteria. Its optimal dose remains unresolved.
2.5K
2 Sources, first seen ago
A team led by researchers at the Helmholtz Institute for Pharmaceutical Research Saarland found that argyrin B can curb Clostridioides difficile in preclinical experiments without causing the same broad disruption to gut bacteria seen with many antibiotics. The findings come from laboratory tests and a mouse infection model, not a human clinical trial.
The researchers screened 259 natural products made by myxobacteria, soil-dwelling microbes that produce compounds to compete with other microorganisms. Argyrin B was active against two laboratory strains and a panel of 51 clinical isolates at low nanogram-per-milliliter concentrations.
—
Not ranked yet
—
Not ranked yet
In separate tests, the compound did not inhibit six selected gut bacterial species at concentrations up to 40 times its MIC90, the concentration that stopped 90% of the clinical isolates. The study therefore describes argyrin B as narrow-spectrum, although those tests do not show that every beneficial gut species would be unaffected.
For the mouse experiment, animals received an antibiotic before infection and then oral argyrin B at 1 or 5 milligrams per kilogram on three consecutive days. Both doses significantly reduced fecal C. difficile counts by day three, with activity the researchers said was similar to a 50-milligram-per-kilogram vancomycin group in this model. That comparison does not establish that argyrin B would be more potent or effective in people.
Argyrin B targets elongation factor G, a protein bacteria use to build other proteins. The researchers found that the compound was barely absorbed into the bloodstream of mice after oral dosing and instead reached high concentrations in the colon, where C. difficile infections occur.
Microbiome analysis also found that argyrin B-treated mice retained key commensal bacteria that were depleted after vancomycin treatment. The Helmholtz Centre for Infection Research says those properties make the compound a potential candidate for a more targeted treatment. Resistant laboratory mutants did emerge, though at a low measured frequency, through changes in the gene encoding the drug target.
The work is still preclinical. Untreated mice in this model eventually cleared the infection on their own, so the experiment did not fully reproduce the persistence or recurrence seen in human disease. The study also did not test whether preserving more of the microbiome actually lowers relapse risk.
Researchers still need to define a therapeutic window, determine the optimal dose and test the compound in recurrent-infection models. Medical Xpress reports that those follow-up studies are planned. Human safety and efficacy remain untested.
